Goldberg Michael D, Vadera Natasha, Yandrapalli Srikanth, Frishman William H
From the Division of Endocrinology, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY.
Department of Family Medicine, Strong Memorial Medical Center, University of Rochester, Rochester, NY.
Cardiol Rev. 2018 Nov/Dec;26(6):307-311. doi: 10.1097/CRD.0000000000000215.
Acromegaly is a rare endocrine disorder that carries a significant burden of cardiovascular morbidity and mortality. Abnormalities of the growth hormone/insulin-like growth factor-1 axis in acromegaly lead to the characteristic cardiovascular manifestations of this disease. One hallmark feature of the disease is acromegalic cardiomyopathy, a syndrome of progressive cardiac dysfunction characterized by left ventricular hypertrophy, diastolic dysfunction, and combined systolic and diastolic dysfunction in the very advanced stage. In this article, we review the current concepts regarding the pathophysiology of acromegalic cardiomyopathy and discuss the various risk factors for its development. We also explore the question of whether the alterations in cardiac function are reversible with successful biochemical control of growth hormone excess either medically or surgically.
肢端肥大症是一种罕见的内分泌紊乱疾病,会带来严重的心血管发病和死亡负担。肢端肥大症中生长激素/胰岛素样生长因子-1轴的异常会导致该疾病典型的心血管表现。该疾病的一个标志性特征是肢端肥大性心肌病,这是一种进行性心脏功能障碍综合征,其特征为左心室肥厚、舒张功能障碍,在疾病晚期还会出现收缩和舒张功能联合障碍。在本文中,我们回顾了有关肢端肥大性心肌病病理生理学的当前概念,并讨论其发展的各种危险因素。我们还探讨了通过药物或手术成功控制生长激素过量后,心脏功能的改变是否可逆的问题。